Pharma package delay disappoints EFPIA
This article was originally published in Scrip
EFPIA, the European pharmaceutical industry association, regrets the European Commission's delay in issuing its package of pharmaceutical legislation. The commission was expected to release a series of proposals on allowing companies to communicate directly with patients, pharmacovigilance and anti-counterfeiting measures, along with a communication on the future of the EU single market in pharmaceuticals, but this has been postponed indefinitely (Scrip Online, October 22nd, 2008).
You may also be interested in...
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.